Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: An in vivo and in vitro study

Cellular Physiology and Biochemistry

Volumn 30, Issue 4, 2012, Pages 876-888

  Lupescu, Adrian ^a   Shaik, Nazneen ^a   Jilani, Kashif ^a   Zelenak, Christine ^a   Lang, Elisabeth ^a   Pasham, Venkanna ^a   Zbidah, Mohanad ^a   Plate, Ansgar ^c   Bitzer, Michael ^b   Föller, Michael ^d   Qadri, Syed M ^a   Lang, Florian ^a  

^a Department of Physiology ^*  (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Helios Klinik Bad Gandersheim   (Germany)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Calcium; Cell volume; Eryptosis; Oxidative stress; Phosphatidylserine; Sorafenib

Indexed keywords

ACETYLCYSTEINE; ADENOSINE TRIPHOSPHATE; CALCIUM; DICHLORODIHYDROFLUORESCEIN DIACETATE; HEMOGLOBIN; LIPOCORTIN 5; LUCIFERASE; SORAFENIB; TIRON;

ANEMIA; ANTIGEN BINDING; ARTICLE; ASSAY; CANCER CHEMOTHERAPY; CELL VOLUME; CONTROLLED STUDY; DRUG BINDING; DRUG EXPOSURE; DRUG SAFETY; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; FLUORESCENCE; HEMOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 84865058970     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000341465     Document Type: Article

References (78)

1. Abou-Alfa GK, Saltz LB: Doxorubicin and sorafenib for treatment of advanced hepatocellular cancer. Gastroenterology 2011;141:e19-e20.
2. Duntas LH, Bernardini R: Sorafenib: rays of hope in thyroid cancer. Thyroid 2010;20:1351-1358.
3. Escudier B: Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther 2011;11:825-836.
4. Gounder MM, Lefkowitz RA, Keohan ML, D'Adamo DR, Hameed M, Antonescu CR, Singer S, Stout K, Ahn L, Maki RG: Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 2011;17:4082-4090.
5. Guan YS, He Q: Sorafenib: activity and clinical application in patients with hepatocellular carcinoma. Expert Opin Pharmacother 2011;12:303-313.
6. Semrad TJ, Gandara DR, Lara PN Jr: Enhancing the clinical activity of sorafenib through dose escalation: rationale and current experience. Ther Adv Med Oncol 2011;3:95-100.
7. Zhang Z, Zhou X, Shen H, Wang D, Wang Y: Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med 2009;7:41.
8. Zhu AX: Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK) ? BMC Med 2009;7:42.
9. Zhang J, Gold KA, Kim E: Sorafenib in non-small cell lung cancer. Expert Opin Investig Drugs 2012; in press.
10. Matsuda Y, Fukumoto M: Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled. Med Mol Morphol 2011;44:183-189.
11. Chapuy B, Schuelper N, Panse M, Dohm A, Hand E, Schroers R, Truemper L, Wulf GG: Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation. Br J Haematol 2011;152:401-412.
12. Fecteau JF, Bharati IS, Ohayre M, Handel TM, Kipps TJ, Messmer D: Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and Mcl-1. Mol Med 2012;18:19-28.
13. Huynh H, Choo SP, Toh HC, Tai WM, Chung AY, Chow PK, Ong R, Soo KC: Comparing the Efficacy of Sunitinib with Sorafenib in Xenograft Models of Human Hepatocellular Carcinoma: Mechanistic Explanation. Curr Cancer Drug Targets 2011;11:944-953.
14. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, Wang XY, Dai Z, Peng YF, Gu CY, Qiu SJ, Fan J: Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy 2011;7:1159-1172.
15. Fernando J, Sancho P, Fernandez-Rodriguez CM, Lledo JL, Caja L, Campbell J, Fausto N, Fabregat I: Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli. J Cell Physiol 2012;227:1319-1325.
16. Huber S, Oelsner M, Decker T, Zum Buschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I: Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 2011;25:838-847.
17. Hartmann JT, Haap M, Kopp HG, Lipp HP: Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab 2009;10:470-481.
18. Mancuso A, Airoldi A, Vigano R, Pinzello G: Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Dig Liver Dis 2011;43:754.
19. Rombola F, Caravetta A, Mollo F, Spinoso A, Peluso L, Guarino R: Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. Acta Medica (Hradec Kralove) 2011;54:177-179.
20. Lang F, Gulbins E, Lerche H, Huber SM, Kempe DS, Foller M: Eryptosis, a window to systemic disease. Cell Physiol Biochem 2008;22:373-380.
21. 2+ leak of human erythrocytes. Cell Physiol Biochem 2008;21:183-192.
22. Foller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Floride E, Schleicher E, Schulz E, Munzel T, Lang F: Regulation of erythrocyte survival by AMP-activated protein kinase. FASEB J 2009;23:1072-1080.
23. + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. J Clin Invest 1993;92:520-526. (Pubitemid 23209038)
24. + channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003;285:C1553-C1560. (Pubitemid 37429630)
25. Berg CP, Engels IH, Rothbart A, Lauber K, Renz A, Schlosser SF, Schulze-Osthoff K, Wesselborg S: Human mature red blood cells express caspase-3 and caspase-8, but are devoid of mitochondrial regulators of apoptosis. Cell Death Differ 2001;8:1197-1206. (Pubitemid 34048474)
26. Lang F, Gulbins E, Lang PA, Zappulla D, Foller M: Ceramide in suicidal death of erythrocytes. Cell Physiol Biochem 2010;26:21-28.
27. Klarl BA, Lang PA, Kempe DS, Niemoeller OM, Akel A, Sobiesiak M, Eisele K, Podolski M, Huber SM, Wieder T, Lang F: Protein kinase C mediates erythrocyte "programmed cell death" following glucose depletion. Am J Physiol Cell Physiol 2006;290:C244-C253.
28. Bhavsar SK, Bobbala D, Xuan NT, Foller M, Lang F: Stimulation of suicidal erythrocyte death by alpha-lipoic acid. Cell Physiol Biochem 2010;26:859-868.
29. Foller M, Huber SM, Lang F: Erythrocyte programmed cell death. IUBMB Life 2008;60:661-668.
30. Foller M, Mahmud H, Gu S, Wang K, Floride E, Kucherenko Y, Luik S, Laufer S, Lang F: Participation of leukotriene C (4) in the regulation of suicidal erythrocyte death. J Physiol Pharmacol 2009;60:135-143.
31. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK: In vitro effect of CTAB-and PEG-coated gold nanorods on the induction of eryptosis/ erythroptosis in human erythrocytes. Nanotoxicology 2011, DOI: 10.3109/17435390.2011.625132.
32. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L: Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2011, DOI: 10.1007/s00592-011-0274-0.
33. Foller M, Feil S, Ghoreschi K, Koka S, Gerling A, Thunemann M, Hofmann F, Schuler B, Vogel J, Pichler B, Kasinathan RS, Nicolay JP, Huber SM, Lang F, Feil R: Anemia and splenomegaly in cGKI-deficient mice. Proc Natl Acad Sci U S A 2008;105:6771-6776. (Pubitemid 351754582)
34. Bhavsar SK, Gu S, Bobbala D, Lang F: Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Cell Physiol Biochem 2011;27:547-556.
35. Zelenak C, Eberhard M, Jilani K, Qadri SM, Macek B, Lang F: Protein Kinase CK1alpha Regulates Erythrocyte Survival. Cell Physiol Biochem 2012;29:171-180.
36. Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Lang F: p38 MAPK activation and function following osmotic shock of erythrocytes. Cell Physiol Biochem 2011;28:1279-1286.
37. Bobin-Dubigeon C, Heurgue-Berlot A, Bouche O, Amiand MB, Le Guellec C, Bard JM: A New Rapid and Sensitive LC-MS Assay for the Determination of Sorafenib in Plasma: Application to a Patient Undergoing Hemodialysis. Ther Drug Monit 2011;33:705-710.
38. Ghashghaeinia M, Cluitmans JC, Akel A, Dreischer P, Toulany M, Koberle M, Skabytska Y, Saki M, Biedermann T, Duszenko M, Lang F, Wieder T, Bosman GJ: The impact of erythrocyte age on eryptosis. Br J Haematol 2012;157:606-614.
39. Brand VB, Sandu CD, Duranton C, Tanneur V, Lang KS, Huber SM, Lang F: Dependence of Plasmodium falciparum in vitro growth on the cation permeability of the human host erythrocyte. Cell Physiol Biochem 2003;13:347-356. (Pubitemid 37465150)
40. Bookchin RM, Ortiz OE, Lew VL: Activation of calcium-dependent potassium channels in deoxygenated sickled red cells. Prog Clin Biol Res 1987;240:193-200.
41. Bratosin D, Estaquier J, Petit F, Arnoult D, Quatannens B, Tissier J P, Slomianny C, Sartiaux C, Alonso C, Huart JJ, Montreuil J, Ameisen JC: Programmed cell death in mature erythrocytes: a model for investigating death effector pathways operating in the absence of mitochondria. Cell Death Differ 2001;8:1143-1156. (Pubitemid 34048470)
42. Lang KS, Duranton C, Poehlmann H, Myssina S, Bauer C, Lang F, Wieder T, Huber SM: Cation channels trigger apoptotic death of erythrocytes. Cell Death Differ 2003;10:249-256. (Pubitemid 36553467)
43. Lang KS, Myssina S, Brand V, Sandu C, Lang PA, Berchtold S, Huber SM, Lang F, Wieder T: Involvement of ceramide in hyperosmotic shock-induced death of erythrocytes. Cell Death Differ 2004;11:231-243. (Pubitemid 38159647)
44. Kornhuber J, Tripal P, Reichel M, Muhle C, Rhein C, Muehlbacher M, Groemer TW, Gulbins E: Functional Inhibitors of Acid Sphingomyelinase (FIASMAs): a novel pharmacological group of drugs with broad clinical applications. Cell Physiol Biochem 2010;26:9-20.
45. Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD, Abbruzzese A, Stiuso P: Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis 2011;2:e150.
46. Chiou JF, Tai CJ, Wang YH, Liu TZ, Jen YM, Shiau CY: Sorafenib induces preferential apoptotic killing of a drugand radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther 2009;8:1904-1913.
47. Bhavsar SK, Eberhard M, Bobbala D, Lang F: Monensin induced suicidal erythrocyte death. Cell Physiol Biochem 2010;25:745-752.
48. Braun M, Foller M, Gulbins E, Lang F: Eryptosis triggered by bismuth. Biometals 2009;22:453-460.
49. Eberhard M, Ferlinz K, Alizzi K, Cacciato PM, Faggio C, Foller M, Lang F: FTY720-induced suicidal erythrocyte death. Cell Physiol Biochem 2010;26:761-766.
50. Ghashghaeinia M, Toulany M, Saki M, Bobbala D, Fehrenbacher B, Rupec R, Rodemann HP, Ghoreschi K, Rocken M, Schaller M, Lang F, Wieder T: The NFκB Pathway Inhibitors Bay 11-7082 and Parthenolide Induce Programmed Cell Death in Anucleated Erythrocytes. Cell Physiol Biochem 2011;27:45-54.
51. Lang E, Jilani K, Zelenak C, Pasham V, Bobbala D, Qadri SM, Lang F: Stimulation of suicidal erythrocyte death by benzethonium. Cell Physiol Biochem 2011;28:347-354.
52. Mahmud H, Foller M, Lang F: Arsenic-induced suicidal erythrocyte death. Arch Toxicol 2009;83:107-113.
53. Mahmud H, Mauro D, Qadri SM, Foller M, Lang F: Triggering of suicidal erythrocyte death by amphotericin B. Cell Physiol Biochem 2009;24:263-270.
54. Mahmud H, Mauro D, Foller M, Lang F: Inhibitory effect of thymol on suicidal erythrocyte death. Cell Physiol Biochem 2009;24:407-414.
55. Qadri SM, Bauer J, Zelenak C, Mahmud H, Kucherenko Y, Lee SH, Ferlinz K, Lang F: Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. Cell Physiol Biochem 2011;28:339-346.
56. 2+ -permeable cation channels triggering erythrocyte cell membrane scrambling. Cell Physiol Biochem 2011;28:857-864.
57. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA: Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011;357:171-179.
58. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G Jr, Thornalley PJ, Schleicher E, Wieder T, Lang F: Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006;18:223-232. (Pubitemid 44946977)
59. Myssina S, Huber SM, Birka C, Lang PA, Lang KS, Friedrich B, Risler T, Wieder T, Lang F: Inhibition of erythrocyte cation channels by erythropoietin. J Am Soc Nephrol 2003;14:2750-2757. (Pubitemid 37305637)
60. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F: Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med 2006;84:378-388. (Pubitemid 43673612)
61. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F: Suicidal erythrocyte death in sepsis. J Mol Med 2007;85:273-281.
62. Lang PA, Kasinathan RS, Brand VB, Duranton C, Lang C, Koka S, Shumilina E, Kempe DS, Tanneur V, Akel A, Lang KS, Foller M, Kun JF, Kremsner PG, Wesselborg S, Laufer S, Clemen CS, Herr C, Noegel AA, Wieder T, Gulbins E, Lang F, Huber SM: Accelerated clearance of Plasmodium-infected erythrocytes in sickle cell trait and annexin-A7 deficiency. Cell Physiol Biochem 2009;24:415-428.
63. Siraskar B, Ballal A, Bobbala D, Foller M, Lang F: Effect of amphotericin B on parasitemia and survival of plasmodium berghei-infected mice. Cell Physiol Biochem 2010;26:347-354.
64. Bobbala D, Alesutan I, Foller M, Huber SM, Lang F: Effect of anandamide in Plasmodium Berghei-infected mice. Cell Physiol Biochem 2010;26:355-362.
65. Foller M, Bobbala D, Koka S, Huber SM, Gulbins E, Lang F: Suicide for survival-death of infected erythrocytes as a host mechanism to survive malaria. Cell Physiol Biochem 2009;24:133-140.
66. Koka S, Bobbala D, Lang C, Boini KM, Huber SM, Lang F: Influence of paclitaxel on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol Biochem 2009;23:191-198.
67. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F: Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
68. Kempe DS, Lang PA, Duranton C, Akel A, Lang KS, Huber SM, Wieder T, Lang F: Enhanced programmed cell death of iron-deficient erythrocytes. FASEB J 2006;20:368-370. (Pubitemid 46671174)
69. Birka C, Lang PA, Kempe DS, Hoefling L, Tanneur V, Duranton C, Nammi S, Henke G, Myssina S, Krikov M, Huber SM, Wieder T, Lang F: Enhanced susceptibility to erythrocyte "apoptosis" following phosphate depletion. Pflugers Arch 2004;448:471-477. (Pubitemid 39141524)
70. Qadri SM, Mahmud H, Lang E, Gu S, Bobbala D, Zelenak C, Jilani K, Siegfried A, Foller M, Lang F: Enhanced suicidal erythrocyte death in mice carrying a loss of function mutation of the Adenomatous Polyposis Coli gene. J Cell Mol Med 2012;16:1085-1093.
71. 2 increases? J Cardiometab Syndr 2008;3:30-34.
72. Andrews DA, Low PS: Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82. (Pubitemid 29342520)
73. Closse C, Dachary-Prigent J, Boisseau MR: Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302. (Pubitemid 29530214)
74. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS: Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627. (Pubitemid 36857838)
75. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M: Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709. (Pubitemid 350058263)
76. Wood BL, Gibson DF, Tait JF: Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flowcytometric measurement and clinical associations. Blood 1996;88:1873-1880. (Pubitemid 26307087)
77. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH: Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007;27:414-421.
78. Zwaal RF, Comfurius P, Bevers EM: Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62:971-988. (Pubitemid 40655614)